ABSTRACT
A 6-year-old girl with Gianotti-Crosti syndrome, which appeared to be caused by a reactivation of Epstein-Barr virus (EBV), is presented. The patient had had infectious mononucleosis at the age of 3 years. Since the titer of anti-EBV capsid antigen antibody was high at 1,280 and the titer of early antigen DR IgG, which increases during the early stage or reactivation, was high at 80 during the recovery stage, the patient was diagnosed as having Gianotti-Crosti syndrome associated with reactivation of EBV. Its clinical symptoms associated with reactivation of EBV were similar to those of that associated with primary EBV infection, in that the present patient had acrolocated papulovesicular dermatitis, superficial lymph node enlargement and mild hepatopathy. This patient provides valuable information in that reactivation was also observed with EBV like other types of herpesvirus.
Subject(s)
Acrodermatitis/pathology , Herpesvirus 4, Human/isolation & purification , Infectious Mononucleosis/pathology , Virus Activation , Acrodermatitis/complications , Acrodermatitis/drug therapy , Biopsy, Needle , Child , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Immunohistochemistry , Infectious Mononucleosis/complications , Infectious Mononucleosis/drug therapy , Risk Assessment , Severity of Illness IndexABSTRACT
We report a rare case of sclerodermatous chronic graft-versus-host disease (GVHD) in a 6-year-old boy that occurred after bone marrow transplantation for his aplastic anemia. The clinical manifestation and histopathologic findings were typical of scleroderma. Although various kinds of treatment have been tried for scleroderma, no established therapy exists. Furthermore, treating this disease is even more difficult in children. In the future, clarification of the pathogenesis of chronic GVHD and establishment of therapy will be necessary.
Subject(s)
Anemia, Aplastic/surgery , Bone Marrow Transplantation/adverse effects , Graft vs Host Disease/etiology , Graft vs Host Disease/pathology , Scleroderma, Diffuse/etiology , Scleroderma, Diffuse/pathology , Child , Chronic Disease , Graft vs Host Disease/therapy , Humans , Male , Scleroderma, Diffuse/therapyABSTRACT
Tissue inhibitors of metalloproteinases (TIMP), common inhibitors of matrix proteinases, have cell-promoting activity. We studied the effects of recombinant human tissue inhibitor of metalloproteinases-2 (rh-TIMP-2) on the migration of normal human epidermal keratinocytes (NHEK). An in vitro migration assay revealed that rh-TIMP-2 enhanced random migration (up to 170%, p<0.05) in a dose-dependent manner. When we applied rh-TIMP-2 solution (20 microg/20 microl/wound) daily to full-thickness wounds made with an 8-mm punch on the backs of healthy (n=8), aged (n=9), and diabetic (n=15) rodents, we observed faster wound closure (p<0.05) than in vehicle-treated controls. Accelerated wound closure was dose-dependent (0-20 microg/wound) in diabetic mice (n=6), and the optimal concentration was 10-20 microg of rh-TIMP-2/wound. Histological examinations performed on days 0, 5, 10, 15, and 20 in diabetic mice revealed faster migration of epidermal keratinocytes from wound edges. These results suggest that rh-TIMP-2 plays an important role in wound healing.